REVIEW PAPER
Approaches of Rhodiola kirilowii and Rhodiola rosea field cultivation in Poland and their potential health benefits
 
More details
Hide details
1
Department of Pharmaceutical Biology and Medicinal Plant Biotechnology, Faculty of Pharmacy, Poland
CORRESPONDING AUTHOR
Katarzyna Sykłowska-Baranek   

Department of Pharmaceutical Biology and Medicinal Plant Biotechnology, Faculty of Pharmacy, Poland
 
Ann Agric Environ Med. 2015;22(2):281–285
KEYWORDS
ABSTRACT
Numerous researches have been carried out on plants of the Rhodiola species, especially Rhodiola kirilowii (Regel) Maxim. and Rhodiola rosea. Various compounds have been reported to be isolated from R. kirilowii and R. rosea, including cyanogenic glycosides, monoterpene alcohols and their glycosides, aryl glycosides, phenylethanoids, phenylpropanoids and their glycosides (salidroside and rosavins respectively), as well as flavonoids, flavonlignans, proanthocyanidins and gallic acid derivatives and the latter have free radical scavenging capacity. The benefits claimed for Rhodiola include adapogenic, neuroprotective, anti-depresive anti-tumour and cardioprotective activities. Currently, the adaptogenic activity of Rhodiola compounds are properties evaluated mainly in human clinical trials. The mechanism of the action of Rhodiola extracts include affecting the levels of cortisol and NO by interactions with glucocorticoid receptors directly or via the c-Jun N-terminal protein kinase (JNK) pathway. However, the natural populations of R. rosea in Poland are threatened; therefore, the cultivation of R. rosea and alternative species R. kirilowii might be a possible solution for producing these kinds of plants in Poland in sufficient quantities and quality for pharmaceutical purposes. Lack of proven interaction with other drugs and no confirmed adverse effects during clinical trials encourages further investigation. These herb preparations ought to be studied extensively to establish their position as potential drugs for a variety of diseases.
 
REFERENCES (50)
1.
Raila A, Lugauskas A, Kemzūraitė A, Zvicevičius E, Ragažinskienė O, Railienė M. Different drying technologies and alternation of mycobiots in the raw material of Hyssopus officinalis L. Ann Agric Environ Med. 2009; 16(1): 93–101.
 
2.
Galambosi B. Demand and Availability of Rhodiola rosea L. Raw Material. Bogers R. Craker L, Lange D (eds.). Med Arom Plants Springer. 2006; 223–236.
 
3.
Kelly GS. Rhodiola rosea: a possible plant adaptogen. Alter Medicine Rev. 2001; 6(3): 293–302.
 
4.
Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomed. 2010; 17(7): 481–493.
 
5.
Kołodziej B, Sugier D. Selected elements of biology and morphology of Roseroot in south – eastern Poland. Acta Sci. Pol Hortorum Cultus. 2012; 11(5): 127–142.
 
6.
Platikanov S, Evstatieva L. Introduction of wild golden root (Rhodiala rosea L.) as a potential economic crop in Bulgaria. Economic Botany 2008; 64(4): 621–627.
 
7.
Krajewska-Patan A, Furmanowa M, Dreger M, Mścisz A, Mielcarek S, Kania M et al. Rhodiola kirilowii – the present status and perspectives of medicinal use Part I. In vivo and in vitro cultivation as well as phytochemical investigations of extracts of roots and callus tissues. Herba Pol. 2008; 54(4): 140–157.
 
8.
Buchwald W, Mścirz A, Krajewska-Patan A, Furmanowa M, Mielcarek S. Mrozinkiewicz PM. Contents of biologically active compounds in Rhodiola rosea during vegetation period. Herba Pol. 2006; 52(4): 34–43.
 
9.
Kucharski W, Mordalski R, Buchwald W, Mielcarek S. Roseroot – the comparison of tillage in conventional and ecological system. J Res Appl Agric Eng. 2011; 56(3): 232–235.
 
10.
Saratikov AS, Krasnov EA, Khnikina LA, Duvidson LM. Isolation and chemical analysis of individual biologically active constituents of Rhodiola rosea. Proc Siberian Acad Sc Biol. 1967; 1: 54–60.
 
11.
Rohloff J. Volatiles from rhizomes of Rhodiola rosea L. Phytochem. 2002; 59(6): 655–661.
 
12.
Kurkin VA, Zapesochnaya GG. Chemical composition and pharmaco-logical characteristics of Rhodiola rosea. J Med Plants. 1985; 1231–1445.
 
13.
Yousef GG, Grace MH, Cheng DM, Belolipov IV, Raskin I, Lila MA. Comparative phytochemical characterization of three Rhodiola species. Phytochem. 2006; 67(21): 2380–2391.
 
14.
Krasnov EA, Kuvaiev VB, Chorużaya TG. Chemotaksonomic investigations of Rhodiola sp. Rast Res. 1978; 14(2): 153–160.
 
15.
Wiedenfeld H, Zych M, Buchwald W, Furmanowa M. New compounds from Rhodiola kirilowii. Scientia Pharm. 2007; 34: 29–34.
 
16.
Wojtyła A. Differences in health – a global problem and its various aspects. Ann Agric Environ Med. 2011; 18(2): 191–192.
 
17.
Krzyzak M, Maslach D, Juczewska M, Lasota W, Rabczenko D, Marcinkowski J, Szpak A. Differences in breast cancer incidence and stage distribution between urban and rural female population in Podlaskie Voivodship, Poland in years 2001–2002. Ann Agric Environ. Med. 2010; 17(1): 159–162.
 
18.
Bojar I, Cvejić R, Głowacka MD, Koprowicz A, Humeniuk E, Owoc A. Morbidity and mortality due to cervical cancer in Poland after introduction of the Act – National Programme for Control of Cancerous Diseases. Ann Agric Environ Med. 2012; 19(4): 680–685.
 
19.
Wójcik R, Siwicki AK, Skopińska-Rózewska E, Wasiutyński A, Sommer E, Furmanowa M. The effect of Chinese medicinal herb Rhodiola kirilowii extracts on cellular immunity in mice and rats. Pol J Vet Sci. 2009; 12(3): 399–405.
 
20.
Siwicki AK, Skopińska-Różewska E, Wasiutyński A, Wójcik R, Zdanowski R, Sommer E. The effect of Rhodiola kirilowii extracts on pigs’ blood leukocytes metabolic (RBA) and proliferative (LPS) activity, and on the bacterial infection and blood leukocytes number in mice. Centr Eur J Immunol. 2012; 37(2): 145–150.
 
21.
Zuo G, Li Z, Chen L, Xu X. Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res. 2007; 76(1): 86–92.
 
22.
Wang H, Ding Y, Zhou J, Sun X, Wang S. The in vitro and in vivo antiviral effects of salidroside from Rhodiola rosea L. against coxsackievirus B3. Phytomed. 2009;16(2–3): 146–155.
 
23.
Chen QG, Zeng YS, Qu ZQ, Tang JY. Qin YJ, Chung P, et al. The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats. Phytomed. 2009; 16(9): 830–838.
 
24.
Van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol. 2009; 22(2): 397–401.
 
25.
Wu T, Zhou H, Jin Z, Bi S, Yang X, Yi D, et al. Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage to cellular proteins. Eur Jo Pharmacol. 2009; 613(1–3): 93–99.
 
26.
Cheng YZ, Chen LJ. Lee WJ, Chen MF, Jung Lin H, Cheng JT. Increase of myocardial performance by Rhodiola-ethanol extract in diabetic rats. J Ethnopharmacol. 2012; 2: 234–239.
 
27.
Mao G, Wang Y, Qiu Q, Yuan L, Li R, et al. Salidroside protects human fibroblast cells from premature senescence induced by H 2 O 2 partly through modulating oxidative status. Mech Ageing Dev. 2010; (11–12): 723–731.
 
28.
Calcabrini C, De Bellis R, Mancini U, Cucchiarini L, Potenza L, De Sanctis R, et al. Rhodiola rosea ability to enrich cellular antioxidant defences of cultured human keratinocytes. Arch Dermatol Res. 2010; 302 (3): 191–200.
 
29.
Li QY, Wang HM, Wang ZQ, Ma JF, Ding JQ, Chen SD. Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells. Neurosc lett. 2010; 481(3): 154–158.
 
30.
Sun C, Wang Z, Zheng Q, Zhang H. Salidroside inhibits migration and invasion of human fibrosarcoma HT1080 cells. Phytomed. 2012; 19(3–4): 355–363.
 
31.
Cai Z, Li W, Wang H, Yan W, Zhou Y, Wang G, et al. Antitumor effects of a purified polysaccharide from Rhodiola rosea and its action mechanism. Carbohyd Polymers 2012; 90(1): 1296–300.
 
32.
Zdanowski R, Skopińska-Rózewska E, Wasiutyński A, Skopiński P, Siwicki, AK, Sobiczewska E, et al. The effect of Rhodiola kirilowii extracts on tumor-induced angiogenesis in mice. Centr Eur J Immunol. 2012; 37(2): 131–139.
 
33.
Cao LL, Guan-Hua D, Min-Wei W. The effect of salidroside on cell damage induced by glutamate and intracellular free calcium in PC12 cells. J Asian Nat Prod Res. 2006; 8(1–2): 159–165.
 
34.
Yu S, Shen Y, Liu J, Ding F. Involvement of ERK1/2 pathway in neuroprotection by salidroside against hydrogen peroxide-induced apoptotic cell death. J Mol Neurosci. 2010; 40(3): 321–331.
 
35.
Shi TS, Feng J, Xing Y, Wu X, Li N, Zhang Z, et al. Neuroprotective effects of Salidroside and its analogue tyrosol galactoside against focal cerebral ischemia in vivo and H 2 O 2 -induced neurotoxicity in vitro. Neurotoxicity Res. 2012; 21(4): 358–367.
 
36.
Olsson EM, Schéele B, Panossian A. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009; 75(2): 2105–2112.
 
37.
Panossian A, Nikoyan N, Ohanyan N, Hovhannisyan A, Abrahamyan H, Gabrielyan E, et al. Comparative study of Rhodiola preparations on behavioral despair of rats. Phytomed. 2008; 15(1–2): 84–91.
 
38.
Panossian A, Wikman G. Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. Curr Clin Pharmacol. 2009; 4(3): 198–219.
 
39.
Wiegant FA, Surinova S, Ytsma E, Langelaar-Makkinje M, Wikman G, Post JA. Plant adaptogens increase lifespan and stress resistance in C. elegans. Biogerontology. 2009; 10(1): 27–42.
 
40.
Abidov M, Grachev S, Seifulla RD, Ziegenfuss TN. Extract of Rhodiola rosea radix reduces the level of C-reactive protein and creatinine kinase in the blood. Bull Exp Biol Med. 2004; 138(1): 63–64.
 
41.
Li M, Donglian C, Huaixing L, Bende T, Lihua S, Ying W. Anti-fatigue effects of salidroside in mice J Medical Coll PLA. 2008; 23(2): 88–93.
 
42.
Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Alter Complem Med. 2008; 14(2): 175–180.
 
43.
Chen CH, Chan HC, Chu YT,. Ho HY, Chen PY, Lee TH, et al. Antioxidant activity of some plant extracts towards xanthine oxidase, lipoxygenase and tyrosinase. Molecules 2009; 8: 2947–2958.
 
44.
Skopińska-Rózewska E, Malinowski M, Wasiutyński A, Sommer E, Furmanowa M, Mazurkiewicz M et al. The influence of Rhodiola quadrifida 50% hydro-alcoholic extract and salidroside on tumor-induced angiogenesis in mice. Pol J Vet Sci. 2008; 11(2): 97–104.
 
45.
Zhang L, Yu H, Sun Y, Lin X, Chen B, Tan C, et al. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol. 2007; 564(1–3): 18–25.
 
46.
Wang H, Zhou G, Gao X, Wang Y, Yao W. Acetylcholinesterase inhibitory-active components of Rhodiola rosea L. Food Chem. 2007; 105(1): 24–27.
 
47.
Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue-a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomed. 2000; 7(5): 365–371.
 
48.
Spasov AA, Wikman GK, Mandrikov VB, Mironova IANeumoin VV. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomed. 2000; 7(2): 85–89.
 
49.
Shevtsov VA, Zholus BI, Shervarly VI, Vol VB, Korovin YP. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control. Phytomed. 2003; 10(2–3): 95–105.
 
50.
Aslanyan G, Amroyan E, Gabrielyan E, Nylander M, Wikman G, Panossian A. Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions. Phytomed. 2010; 17(7): 494–499.
 
eISSN:1898-2263
ISSN:1232-1966